CBL Stock Overview
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Control Bionics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.043 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.037 |
| Beta | -0.024 |
| 1 Month Change | -4.44% |
| 3 Month Change | -8.51% |
| 1 Year Change | -71.33% |
| 3 Year Change | -93.86% |
| 5 Year Change | n/a |
| Change since IPO | -96.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBL | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 7.5% | 1.4% | 0.03% |
| 1Y | -71.3% | 14.5% | 4.2% |
Return vs Industry: CBL underperformed the Australian Medical Equipment industry which returned 13.9% over the past year.
Return vs Market: CBL underperformed the Australian Market which returned 6% over the past year.
Price Volatility
| CBL volatility | |
|---|---|
| CBL Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 10.1% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CBL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CBL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Jeremy Steele | www.controlbionics.com |
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that can be used with a Windows display device; NeuroNode, a wireless wearable sensor that gives the user the ability to access their technology by bioelectric signals or spatial movements; Uno Touch, a speech generating device; NeuroNode Duo, a wireless sensor; and Eye gaze Duo that allows the user to control a computer mouse with their eyes.
Control Bionics Limited Fundamentals Summary
| CBL fundamental statistics | |
|---|---|
| Market cap | AU$7.34m |
| Earnings (TTM) | -AU$4.82m |
| Revenue (TTM) | AU$5.71m |
1.3x
P/S Ratio-1.5x
P/E RatioIs CBL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBL income statement (TTM) | |
|---|---|
| Revenue | AU$5.71m |
| Cost of Revenue | AU$1.51m |
| Gross Profit | AU$4.20m |
| Other Expenses | AU$9.02m |
| Earnings | -AU$4.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 73.53% |
| Net Profit Margin | -84.45% |
| Debt/Equity Ratio | 0% |
How did CBL perform over the long term?
See historical performance and comparison